CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Revenues:
Net product sales	$ 834,219	$ 657,819	$ 1,618,401	$ 1,202,392
Sanofi collaboration revenue	163,414	195,110	383,108	368,466
Bayer Collaboration Revenue	191,896	134,237	371,488	258,083
Other revenue	23,100	11,451	40,481	39,288
Total revenues	1,212,629	998,617	2,413,478	1,868,229
Expenses:
Research and development	559,930	390,330	1,030,042	733,443
Selling, general, and administrative	292,038	174,588	581,715	333,579
Cost of goods sold	41,247	60,855	120,189	103,425
Cost of collaboration and contract manufacturing	27,786	27,985	60,596	69,370
Total expenses	921,001	653,758	1,792,542	1,239,817
Income from operations	291,628	344,859	620,936	628,412
Other income (expense):
Investment income	2,801	1,653	5,050	1,833
Interest and other expense, net	(2,173)	(18,516)	(3,579)	(25,726)
Nonoperating Income (Expense)	628	(16,863)	1,471	(23,893)
Income before income taxes	292,256	327,996	622,407	604,519
Income tax expense	(96,038)	(133,353)	(244,804)	(333,855)
Net income	$ 196,218	$ 194,643	$ 377,603	$ 270,664
Net income per share - basic	$ 1.88	$ 1.89	$ 3.61	$ 2.64
Net income per share - diluted	$ 1.69	$ 1.69	$ 3.24	$ 2.35
Weighted average shares outstanding - basic	104,633	102,886	104,462	102,558
Weighted average shares outstanding - diluted	116,231	115,259	116,617	114,962
Statements of Comprehensive Income
Net income	$ 196,218	$ 194,643	$ 377,603	$ 270,664
Other comprehensive income (loss):
Unrealized loss on marketable securities, net of tax	840	(28,751)	(3,368)	(33,098)
Comprehensive income	$ 197,058	$ 165,892	$ 374,235	$ 237,566